Table 1.
Characteristics of 40 children and adolescents (study population) from the Danish Remission Phase Cohort and the entire cohort, respectively.
| Study Population | 1 Month | 3 Months | 6 Months | 12 Months | 60 Months |
|---|---|---|---|---|---|
| n (girls/n) | 40 (24) | 37 (22) | 33 (19) | 34 (20) | 38 (23) |
| Age at diagnosis (years) | 8.7 (3.4) | - | - | - | - |
| HbA1c (DCCT, %) | 9.1 (1.3) | 7.3 (1.1) | 7.8 (1.6) | 7.9 (1.1) | 8.4 (1.0) |
| HbA1c (IFCC,mmol/mol) | 76 (14.2) | 56 (12.0) | 62 (17.5) | 63 (12.0) | 68 (11.0) |
| C-peptide (pmol/L) | 629 (371) | 528 (323) | 436 (333) | 257 (251) | 62 (76) |
| IDAA1c | 10.8 (2.0) | 9.2 (1.5) | 10.1 (2.2) | 11.0 (1.8) | 12.0 (1.9) |
| Insulin dose (units/kg/24 h) | 0.45 (0.27) | 0.47 (0.23) | 0.58 (0.26) | 0.78 (0.27) | 0.88 (0.32) |
| Autoantibody positivity (%) | |||||
| GAD65A | 55 | 62 | 61 | 56 | 55 |
| IA | 80 | 100 | 100 | 100 | 78 |
| IA-2A | 73 | 68 | 70 | 68 | 74 |
| ICA | 93 | 92 | 94 | 94 | 92 |
| ZnT8tripleAb | 65 | 70 | 75 | 76 | 26 |
Data are presented as means (SD), unless otherwise stated. SCP: stimulated C-peptide. IDAA1c = HbA1c (percent) + [4 × insulin dose (units per kilogram per 24 h)]. GAD65A: autoantibodies against glutamic acid decarboxylase (GAD). IA: insulin autoantibodies. IA-2A: islet antigen 2 antibody. ICA: islet-cell antibody. ZnT8tribleAb: Zinc transporter 8 triple mix antibody variant containing the isotypes glutamine, arginine, and tryptophan. Missing data are either due to no visit, missing or lost sample, or drop-out.